glandular and epithelial neoplasms

Summary

Summary: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.

Top Publications

  1. ncbi Nucleolar organizer regions as a prognostic indicator in epithelial cancers of the ovary
    Shatrughan Prasad Sah
    Department of Pathology, B P Koirala Institute of Health Sciences, Dharan, Nepal
    Int J Gynecol Pathol 23:347-53. 2004
  2. ncbi Green tea consumption enhances survival of epithelial ovarian cancer
    Min Zhang
    School of Public Health, Curtin University of Technology, Perth, WA, Australia
    Int J Cancer 112:465-9. 2004
  3. ncbi Advances in the management of epithelial ovarian cancer
    Anna Berkenblit
    Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Reprod Med 50:426-38. 2005
  4. ncbi [Epithelial ovarian cancer]
    F Hilpert
    Klinik fur Gynakologie und Geburtshilfe, Universitatsklinikum Schleswig Holstein, Campus Kiel
    Ther Umsch 64:375-80. 2007
  5. pmc Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Onc
    Seena C Aisner
    Department of Pathology, UMDNJ NJMS, Newark, New Jersey, USA
    J Thorac Oncol 5:885-92. 2010
  6. ncbi Ovarian cancer: strategies for overcoming resistance to chemotherapy
    Roshan Agarwal
    Section of Medicine, Institute for Cancer Research, Sutton, Surrey SM2 5NG, UK
    Nat Rev Cancer 3:502-16. 2003
  7. ncbi Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm
    Mahul B Amin
    Department of Pathology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 33:393-400. 2009
  8. ncbi Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study
    Robert A Burger
    University of California, Irvine Medical Center, Building 56, Room 264, 101 The City Dr, Orange, CA 92868, USA
    J Clin Oncol 25:5165-71. 2007
  9. ncbi Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Stephen A Cannistra
    Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 25:5180-6. 2007
  10. ncbi Association of lymphadenectomy and survival in stage I ovarian cancer patients
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA 94305, USA
    Obstet Gynecol 109:12-9. 2007

Detail Information

Publications225 found, 100 shown here

  1. ncbi Nucleolar organizer regions as a prognostic indicator in epithelial cancers of the ovary
    Shatrughan Prasad Sah
    Department of Pathology, B P Koirala Institute of Health Sciences, Dharan, Nepal
    Int J Gynecol Pathol 23:347-53. 2004
    ..These observations suggest that AgNOR count holds promise for prediction of tumor aggressiveness in EOCs. However, its role as an independent prognostic variable of patient survival remains questionable...
  2. ncbi Green tea consumption enhances survival of epithelial ovarian cancer
    Min Zhang
    School of Public Health, Curtin University of Technology, Perth, WA, Australia
    Int J Cancer 112:465-9. 2004
    ..The corresponding dose-response relationships were significant (p < 0.05). We conclude that increasing the consumption of green tea post-diagnosis may enhance epithelial ovarian cancer survival...
  3. ncbi Advances in the management of epithelial ovarian cancer
    Anna Berkenblit
    Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Reprod Med 50:426-38. 2005
    ....
  4. ncbi [Epithelial ovarian cancer]
    F Hilpert
    Klinik fur Gynakologie und Geburtshilfe, Universitatsklinikum Schleswig Holstein, Campus Kiel
    Ther Umsch 64:375-80. 2007
    ....
  5. pmc Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Onc
    Seena C Aisner
    Department of Pathology, UMDNJ NJMS, Newark, New Jersey, USA
    J Thorac Oncol 5:885-92. 2010
    ..Three markers, EGFR, C-kit, and Her2/neu, were selected for evaluation in patients with advanced thymic epithelial tumors treated on E1C97...
  6. ncbi Ovarian cancer: strategies for overcoming resistance to chemotherapy
    Roshan Agarwal
    Section of Medicine, Institute for Cancer Research, Sutton, Surrey SM2 5NG, UK
    Nat Rev Cancer 3:502-16. 2003
    ..A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved...
  7. ncbi Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm
    Mahul B Amin
    Department of Pathology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 33:393-400. 2009
    ..Thyroid-like follicular renal cell carcinoma represents a unique histologic subtype of renal cell carcinoma of low malignant potential and its primary importance is to distinguish it from metastatic carcinoma from the thyroid...
  8. ncbi Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study
    Robert A Burger
    University of California, Irvine Medical Center, Building 56, Room 264, 101 The City Dr, Orange, CA 92868, USA
    J Clin Oncol 25:5165-71. 2007
    ..We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody...
  9. ncbi Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Stephen A Cannistra
    Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 25:5180-6. 2007
    ....
  10. ncbi Association of lymphadenectomy and survival in stage I ovarian cancer patients
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA 94305, USA
    Obstet Gynecol 109:12-9. 2007
    ..To estimate the survival impact of lymphadenectomy in women diagnosed with clinical stage I ovarian cancer...
  11. ncbi Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer
    Shelley S Tworoger
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer 112:1169-77. 2008
    ..Therefore, the associations between these exposures and ovarian cancer risk were prospectively examined among 110,454 women in the Nurses' Health Study (NHS) for the smoking analyses and 80,253 women for the dietary analyses...
  12. ncbi Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?
    Rong Yu Zang
    Department of Gynecologic Oncology, Cancer Hospital of Fudan University formerly Shanghai Medical University, Shanghai, China
    Cancer 100:1152-61. 2004
    ....
  13. pmc Serum protein markers for early detection of ovarian cancer
    Gil Mor
    Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 102:7677-82. 2005
    ..However, the combination of the four analytes exhibited the following: sensitivity 95%, positive predictive value (PPV) 95%, specificity 95%, and negative predictive value (NPV) 94%, a considerable improvement on current methodology...
  14. ncbi Gene expression signature with independent prognostic significance in epithelial ovarian cancer
    Dimitrios Spentzos
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 22:4700-10. 2004
    ..In this study, we investigated whether tumor transcription profiling could be used as a prognostic tool in this disease...
  15. ncbi OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal
    C van Haaften-Day
    Gynecologic Cancer Center, The Royal Hospital for Women, Randwick, Sydney, New South Wales, Australia
    Cancer 92:2837-44. 2001
    ..This was true for all stages, including early-stage, potentially curable disease. When used as single markers, however, only the CA-125-II assay could distinguish invasive Stage I tumors from apparently healthy women...
  16. ncbi Benign mixed epithelial and stromal tumor of the kidney
    M Michal
    Department of Pathology, Medical Faculty, Charles University, Pilsen, Czech Republic
    Pathol Res Pract 194:445-8. 1998
    ..Histologically, the tumor differed from the nephrogenic adenofibroma and the rare cases of adult Wilms tumors, mesoblastic nephromas and cystic nephromas...
  17. ncbi Mixed epithelial and stromal tumor of the kidney
    N V Adsay
    Harper Hospital and Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Am J Surg Pathol 24:958-70. 2000
    ..We think this entity is a benign composite neoplasm in which stroma and epithelium are both integral neoplastic components...
  18. ncbi CD44 expression indicates favorable prognosis in epithelial ovarian cancer
    Sari Sillanpää
    Department of Pathology and Forensic Medicine, University of Kuopio and Kuopio University Hospital, Finland
    Clin Cancer Res 9:5318-24. 2003
    ..The purpose of this study was to investigate the expression and prognostic significance of CD44 in epithelial ovarian cancer...
  19. ncbi BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy
    Jennifer E Quinn
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Belfast, United Kingdom
    Clin Cancer Res 13:7413-20. 2007
    ..We investigated whether BRCA1 mRNA expression levels may represent a biomarker of survival in sporadic epithelial ovarian cancer following chemotherapy treatment...
  20. ncbi Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy
    Nilofer S Azad
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer 112:1726-32. 2008
    ..In this pilot study, the authors analyzed the utility of CA125 to predict disease behavior in patients who were receiving sorafenib, a Raf-kinase/VEGFR2 inhibitor, and bevacizumab, an anti-VEGF monoclonal antibody...
  21. ncbi Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk
    Galina Lurie
    Cancer Epidemiology Program, Cancer Research Center of Hawaii, Honolulu, HI 96813, USA
    Cancer Epidemiol Biomarkers Prev 16:2566-71. 2007
    ..1 and OR 5.2, 95% CI 1.6-17.5), but not in Japanese women (OR 1.1, 95% CI 0.6-1.9 and OR 2.3, 95% CI:0.4-12.3). This investigation provides some evidence that polymorphisms in the VDR gene might influence ovarian cancer susceptibility...
  22. ncbi Mixed epithelial and stromal tumors of the kidney. A report of 22 cases
    Michal Michal
    Sikl s Department of Pathology, Laboratore Spec Diagnostiky Medical Faculty Hospital, Charles University Hospital, Alej Svobody 80, 30460 Pilsen, Czech Republic
    Virchows Arch 445:359-67. 2004
    ..In particular, the distinction from cystic nephroma in adult male patients is emphasized, and two cases of this entity are included in the study for comparison...
  23. ncbi Advances in treatment of epithelial ovarian cancer
    Fumitaka Kikkawa
    Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai cho 65, Showa Ku, Nagoya 466 8550, Japan
    Nagoya J Med Sci 68:19-26. 2006
    ..The effectiveness of neoadjuvant chemotherapy and interval debulking surgery still remains unclear. This review will describe the advances in surgical procedures and chemotherapy in treatment of ovarian cancer patients...
  24. ncbi Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group
    D S Alberts
    University of Arizona Cancer Center, 1515 North Campbell Avenue, PO Box 245024, Tucson, AZ 85724 5024, USA
    Int J Gynecol Cancer 14:224-8. 2004
    ....
  25. ncbi Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms
    Giovanna Giordano
    Department of Pathology and Laboratory Medicine, Section of Pathology, Parma University, 43100 Parma, Italy
    Pathol Res Pract 204:163-74. 2008
    ....
  26. ncbi Using the World Health Organization Classification of thymic epithelial neoplasms to describe CT findings
    Noriyuki Tomiyama
    Department of Radiology, Ehime National Hospital, 366, Yokogawara, Shigenobu, Ehime 791 0281, Japan
    AJR Am J Roentgenol 179:881-6. 2002
    ..Our purpose was to assess the CT features of various subtypes of thymic epithelial neoplasms on the basis of the 1999 World Health Organization classification...
  27. ncbi Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas
    I Vassilopoulos
    Department of Pathology, National and Capodistrian University of Athens, Athens, Greece
    Histol Histopathol 18:761-70. 2003
    ....
  28. ncbi Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?
    John K Chan
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Orange, California, USA
    Obstet Gynecol 102:156-61. 2003
    ..Clinical and pathologic factors responsible for survival differences between the two groups were also determined...
  29. ncbi The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer
    S M Eisenkop
    Womens' Cancer Center: Encino-Tarzana, 5525 Etiwanda Avenue, Suite 311, Tarzana, California, 91356, USA
    Gynecol Oncol 82:143-9. 2001
    ..The decision not to perform a lymph node dissection for optimally and completely cytoreduced patients may result in unrecognized macroscopic residual disease that is larger than what would otherwise be documented...
  30. ncbi Patterns and progress in ovarian cancer over 14 years
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, California 94305, USA
    Obstet Gynecol 108:521-8. 2006
    ..To estimate the change in survival rates of women with ovarian cancer during the past 14 years...
  31. ncbi Molecular pathology of epithelial ovarian cancer
    Michael Christie
    Department of Anatomical Pathology, Monash Medical Centre, Clayton, Victoria, Australia
    J Br Menopause Soc 12:57-63. 2006
    ..The identified molecular changes and pathways of development in epithelial ovarian cancer will facilitate the rationalized development of new diagnostic modalities and tailored therapies for this malignancy...
  32. pmc A computational study of the development of epithelial acini: II. Necessary conditions for structure and lumen stability
    Katarzyna A Rejniak
    Division of Mathematics, University of Dundee, Dundee, DD1 4HN, Scotland, UK
    Bull Math Biol 70:1450-79. 2008
    ..Whenever possible, we compare our computational results with known experimental cases of mutant acini...
  33. ncbi Adult mesoblastic nephroma
    L Daniel
    Service d anatomie pathologique et de neuropathologie, Marseille, France
    Pathol Res Pract 196:135-9. 2000
    ..The following differential diagnoses will be discussed: benign mixed epithelial and stromal tumor, metanephric adenoma, and nephrogenic adenofibroma...
  34. ncbi Tumor stroma as the main source of inhibin production in ovarian epithelial tumors
    W Zheng
    Department of Pathology, Los Angeles County and University of Southern California Healthcare Network, USA
    Am J Reprod Immunol 44:104-13. 2000
    ..The aims of this study were to examine the source of elevated inhibin from ovarian epithelial tumors (OETs) and to preliminarily investigate the role of the gonadotropin-inhibin/activin relationship in the development of OET...
  35. pmc A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer
    M J Lind
    University Department of Clinical Oncology, Newcastle General Hospital, Newcastle upon Tyne, UK
    Br J Cancer 65:621-3. 1992
    ..There were five early deaths due to disease progression. The use of goserelin in patients with epithelial ovarian cancers resistant to or relapsing soon after first line platinum based chemotherapy needs to be further evaluated...
  36. ncbi [Analysis of risk factors for epithelial ovarian cancer recurrence]
    Sui Liu
    Department of Gynecology Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, PR China
    Ai Zheng 22:1197-200. 2003
    ..This study was designed to explore the risk factors for the recurrence of epithelial ovarian cancer...
  37. ncbi Nuclear receptor DAX-1 in human common epithelial ovarian carcinoma: an independent prognostic factor of clinical outcome
    Manar Abd-Elaziz
    Department of Pathology, Tohoku University School of Medicine, Aoba ku, Sendai 980 8575
    Cancer Sci 94:980-5. 2003
    ..In conclusion, DAX-1 immunoreactivity is considered to be a new independent marker of poor prognosis or adverse clinical outcome in patients with epithelial ovarian carcinoma, possibly through altering in situ steroids production...
  38. ncbi Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer
    Robert M Wenham
    Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:4396-403. 2003
    ..We have examined whether BRCA2 N372H or common amino acid-changing polymorphisms in BRCA1 predispose to ovarian cancer...
  39. ncbi Management of early ovarian cancer
    Yukio Sonoda
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 18:343-56; discussion 358, 361-2. 2004
    ..Ideally, these patients should have access to a gynecologic oncologist prior to their initial surgical procedure...
  40. ncbi Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma
    Ritu Salani
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, 600 N Wolfe St Phipps 281, Baltimore, Maryland 21224, USA
    Ann Surg Oncol 14:3552-7. 2007
    ....
  41. ncbi Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics
    Kunle Odunsi
    Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14261, USA
    Int J Cancer 113:782-8. 2005
    ..The metabonomic approach deserves further evaluation as a potential novel strategy for the early detection of epithelial ovarian cancer...
  42. ncbi Adjuvant radiotherapy in stage I-II epithelial ovarian cancer
    I Skirnisdottir
    Department of Gynecology and Obstetrics, University Hospital, Uppsala, Sweden
    Eur J Gynaecol Oncol 22:409-16. 2001
    ..The purpose of this study was to assess the efficacy and side-effects of abdominopelvic irradiation applied as adjuvant postoperative therapy in early stage ovarian carcinomas...
  43. ncbi Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma
    Ingiridur Skirnisdottir
    Department of Women s and Children s Health, Obstetrics and Gynecology, University Hospital, Akademiska sjukhuset, SE 751 85 Uppsala, Sweden
    Oncol Rep 18:1249-56. 2007
    ..The spectrum of side effects was also in favor of the monotherapy regimen. Further, larger randomized studies are needed to give a final and fully conclusive answer to this question...
  44. ncbi Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer
    Mahrukh M Hussain
    Medical Oncology Clinical Research Unit, Medical Ovarian Cancer Clinic and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1500, USA
    J Clin Oncol 21:4356-63. 2003
    ..It inhibits angiogenesis, tumor growth, invasion, and metastasis. We hypothesized that CAI would promote disease stabilization lasting >/= 6 months in patients with relapsed ovarian cancer...
  45. ncbi Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary
    Tetsuji Kurokawa
    Department of Obstetrics and Gynecology, Fukui Medical University, Fukui ken, Japan
    Int J Cancer 109:926-32. 2004
    ..760, p=0.0004) by which to predict positive FDG uptake. Therefore, glucose consumption, as determined by analysis of SUVs in FDG-PET, may be a noninvasive biomarker for ovarian epithelial tumors...
  46. ncbi Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors
    Jennifer Byrom
    Institute for Science and Technology in Medicine, Keele University School of Medicine, University Hospital of North Staffordshire, Stoke on Trent, UK
    Int J Oncol 24:1271-7. 2004
    ..However with the completion of the human genome sequencing project several candidate genes are identified...
  47. ncbi Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients
    Samar K Kassim
    Medical Biochemistry Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
    Clin Biochem 37:363-9. 2004
    ..Vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) have been demonstrated to induce angiogenesis in epithelial tumors in vivo...
  48. pmc Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications
    H Gakiopoulou
    First Department of Pathology, Athens University, School of Medicine, GR 11527 Athens, Greece
    Br J Cancer 97:1124-34. 2007
    ..0001 in both relationships). In conclusion, MCM-2 and MCM-5 proteins appear to be promising as prognostic markers in patients with ovarian adenocarcinomas...
  49. ncbi Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer
    Kazushi Shigemasa
    Department of Obstetrics and Gynecology, Hiroshima University Graduate School of Biomedical Sciences, Minami Ku, Hiroshima 734 8551, Japan
    Oncol Rep 11:1153-9. 2004
    ..0304). Expression of hK8 is increased during the development of ovarian cancer and down-regulated during ovarian cancer progression. Expression of hK8 is a favorable prognostic marker in patients with ovarian cancer...
  50. ncbi Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
    Ben Davidson
    Molecular Signaling Section, Laboratory of Pathology, Center for Cancer Research, The National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer 100:2139-47. 2004
    ..The objective of the current study was to evaluate the anatomic site-related and cellular expression of GEP and its association with clinicopathologic parameters and survival in patients with advanced-stage ovarian carcinoma...
  51. ncbi Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
    A Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 19:327-31. 2008
    ..The aim of this retrospective study is to analyze the prognostic value of the CA-125 nadir after the completion of an optimal primary treatment...
  52. ncbi Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study
    Estrid V S Høgdall
    Department of Viruses, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
    Cancer 100:2387-95. 2004
    ..Loss of heterozygosity (LOH) may be detected in individuals heterozygous for an allele and is associated with loss of function of tumor suppressor genes...
  53. ncbi Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma
    Hiroaki Kajiyama
    Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai cho 65, Showa Ku, Nagoya 466 8550, Japan
    Int J Cancer 122:91-9. 2008
    ..The present results suggest that there may be a link between the SDF-1alpha/CXCR4 axis and enhanced intraperitoneal dissemination of EOC and that CXCR4 may be a novel target for the treatment of EOC...
  54. ncbi Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma
    Jun ichi Akahiro
    Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, 1 1 Seiryo machi, Aoba ku, Sendai 980 8574, Japan
    Int J Clin Oncol 9:42-6. 2004
    ..In this study, for the first time, the serum concentration of IL-18 and its significance as a prognostic indicator was evaluated in patients with epithelial ovarian cancer...
  55. pmc A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis
    R Fruscio
    Clinica Ostetrica e Ginecologica, University of Milan Bicocca, San Gerardo Hospital, Monza, Italy
    Br J Cancer 98:720-7. 2008
    ..This unexpected finding might be a consequence of the close surgical surveillance and aggressive chemotherapeutic approach...
  56. ncbi The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer
    Hakan Karagol
    Department of Medical Oncology, Faculty of Medicine, Trakya University, Turkey
    Med Oncol 24:39-43. 2007
    ..In this study, we evaluated efficacy of tamoxifen in our patients with platinum-resistant epithelial ovarian carcinoma...
  57. ncbi Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer
    Amanda Psyrri
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 11:8384-90. 2005
    ..However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of p27 in ovarian cancer using a novel method of compartmentalized in situ protein analysis...
  58. ncbi IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival
    D Katsaros
    Department of Obstetrics and Gynecology, Gynecologic Oncology and Breast Cancer Unit, University of Turin, Turin, Italy
    Eur J Cancer 37:478-85. 2001
    ..Findings of the study indicate that IGFBP-3 may play a role in the progression of epithelial ovarian cancer, but that it has no independent value in predicting either disease prognosis or the response of patients to chemotherapy...
  59. ncbi Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
    J Kaern
    Department of Gynecologic Oncology, University of Oslo, The Norwegian Radium Hospital, Oslo, Norway
    Int J Gynecol Cancer 15:1014-22. 2005
    ..Normal CA125 level before platinum therapy and negative Ki-67 expression also predicted a more favorable prognosis...
  60. ncbi Second-look laparotomy for epithelial ovarian cancer: a reappraisal
    C S Chu
    Division of Gynecologic Oncology, University of Pennsylvania Medical Center, Hospital of the University of Pennsylvania, Philadelphia 19104, USA
    Curr Oncol Rep 3:11-8. 2001
    ..Prospective, randomized, controlled trials are needed to evaluate the various therapies available. In general, the performance of SLL should be confined to those patients enrolled in clinical trials...
  61. ncbi Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors
    Kerry J Rodabaugh
    Department of Gynecologic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York, USA
    Int J Gynecol Pathol 26:10-5. 2007
    ..Furthermore, these results suggest that PDEF is a potential marker and target in ovarian cancer...
  62. ncbi Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine
    Bin Ye
    Laboratory of Gynecologic Oncology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women s Hospital, Harvard Medical School, Dana Farber Cancer Center, 221 Longwood Avenue, LMRC 601B, Boston, MA 02115, USA
    Clin Cancer Res 12:432-41. 2006
    ..The objective was to identify and characterize low molecular weight proteins/peptides in urine and their posttranslational modifications that might be used as a screening tool for ovarian cancer...
  63. ncbi Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer
    Pierluigi Benedetti Panici
    Department of Obstetrics and Gynecology, University of Rome La Sapienza, Viale del Policlinico, 155, 00161, Rome, Italy
    Ann Surg Oncol 14:1136-42. 2007
    ..The aim of this prospective observational trial was to analyze the role of SCR in patients with platinum-sensitive ovarian cancer...
  64. ncbi The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer
    T S Barlow
    Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Int J Gynecol Cancer 16:496-500. 2006
    ..001). In a multivariate analysis using CA125, age, and ascites, the area under the curve was 0.686. We conclude that preoperative serum CA125 did not reliably predict OD in patients with stage III-IV EOC...
  65. ncbi Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer
    Anette Lykke Petri
    Department of Gynaecology and Obstetrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    APMIS 114:359-63. 2006
    ..Serum CA125 levels might therefore be included as a prognostic factor in future clinical trials of stage I EOC...
  66. ncbi Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis
    Amanda Psyrri
    Department of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA
    Cancer Epidemiol Biomarkers Prev 15:1179-83. 2006
    ..Here, we sought to determine the prognostic value of cIAP protein levels in epithelial ovarian cancer using a novel method of compartmentalized in situ protein analysis...
  67. ncbi 18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: in comparison with vascularity, Ki-67, p53, and histologic grade
    Song Mee Cho
    Department of Radiology, Kangnam St Mary s Hospital, The Catholic University of Korea, Seocho go, Banpo dong, 137 701 Seoul, South Korea
    Eur Radiol 17:409-17. 2007
    ..696, 95% CI 0.487-0.993, p=0.0458). In conclusion, FDG PET positivity revealed positive correlation with MVD and mitotic activity. MVD was the strongest parameter in predicting positive tumor recurrence on FDG PET...
  68. ncbi Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking
    Tien Le
    Division of Gynecologic Oncology, Ottawa General Hospital, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
    Ann Surg Oncol 13:1711-6. 2006
    ..To examine the prognostic significance of postoperative morbidities in patients with ovarian cancer treated with neoadjuvant chemotherapy and interval surgical debulking...
  69. ncbi M-CAM expression as marker of poor prognosis in epithelial ovarian cancer
    Daniela Aldovini
    Department of Pathology, S Chiara Hospital, Trento, Italy
    Int J Cancer 119:1920-6. 2006
    ..In particular, M-CAM expression identifies a subgroup of front-line therapy-responding patients who undergo dramatic relapses, thus helping to better select patients who might benefit from new/alternative therapeutic modalities...
  70. ncbi Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?
    Yun Hyun Cho
    Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea
    Gynecol Oncol 103:878-82. 2006
    ..To evaluate the impact on prognosis of complete surgical staging in patients with stage I mucinous epithelial ovarian tumors...
  71. ncbi RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer
    P A Bignone
    Cancer Research UK, Molecular Oncology Laboratories, Ovarian Cancer Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK
    Oncogene 26:683-700. 2007
    ..In contrast, small interfering RNA against RPS6KA2 showed the opposite effect in 41M cells. The above results suggest that RPS6KA2 is a putative tumour suppressor gene to explain allele loss at 6q27...
  72. ncbi Unique gene expression profile based on pathologic response in epithelial ovarian cancer
    Dimitrios Spentzos
    Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 23:7911-8. 2005
    ..We investigated whether tumor tissue obtained at diagnosis expresses a specific gene profile that is predictive of findings at second-look surgery in patients with epithelial ovarian cancer (EOC)...
  73. ncbi Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon
    Rebecca T Marquez
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:6116-26. 2005
    ..This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble...
  74. ncbi The influence of reproductive and hormonal factors on ovarian cancer survival
    C M Nagle
    Cancer and Population Studies Group, Queensland Institute of Medical Research, Brisbane, Australia
    Int J Gynecol Cancer 18:407-13. 2008
    ....
  75. ncbi The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
    Michal Gorovetz
    Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel, and Department of Gynecologic Oncology, National Hospital Norwegian Radium Hospital, Oslo, Norway
    Gynecol Oncol 103:831-40. 2006
    ..To analyze the expression of phospholipase A2 (PLA2) isoforms and its relationship with matrix metalloproteinase (MMP) expression and clinical parameters in advanced-stage (FIGO III-IV) ovarian carcinoma...
  76. ncbi A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer
    Yuji Takei
    Department of Obstetrics and Gynecology, Jichi Medical School, 3311 1 Yakushiji, Minamikawachi, Kawachi, Tochigi 329 0498, Japan
    Oncol Rep 10:951-5. 2003
    ..Although hematological toxicity was relatively marked, this regimen can be applied in Japanese women...
  77. ncbi The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy
    Anil K Sood
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard Unit 440, Houston, Texas 77030, USA
    Cancer Biol Ther 1:661-4. 2002
    ..002) was independently associated with poor survival. This is the first study demonstrating the clinical implications of tumor cell-lined vasculature in ovarian carcinoma...
  78. ncbi The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma
    D D Rosa
    Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK
    Clin Oncol (R Coll Radiol) 19:125-8. 2007
    ..This work was designed to verify whether the neoadjuvant approach had an effect on survival in patients with advanced-stage ovarian cancer...
  79. pmc Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma
    Y Yokoyama
    Department of Obstetrics and Gynaecology, University of Cambridge, The Rose Maternity Hospital, UK
    Br J Cancer 88:237-44. 2003
    ..Since VEGF-D was found to be an independent predictor of poor outcome, its measurement, together with other prognostic markers may improve prospective identification of patients with a poor prognosis...
  80. ncbi Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study
    Naoko Sato
    Department of Obstetrics and Gynecology, Tohoku University School of Medicine, 1 1 Seiryo machi, Aoba ku, Sendai 980 8574, Japan
    Int J Clin Oncol 8:40-4. 2003
    ..In the present study, we conducted a multicenter retrospective analysis to elucidate the prognostic significance of second-look laparotomy (SLL) in early-stage epithelial ovarian cancer that was confirmed by complete surgical exploration...
  81. ncbi Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study
    John K Chan
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco School of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143 1702, USA
    Cancer 112:2202-10. 2008
    ..The purpose was to identify the factors predictive of recurrence and survival in patients with high-risk (stage I, grade 3; stage IC, stage II, or clear cell) epithelial ovarian cancer after adjuvant therapy...
  82. ncbi BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer
    Cécile Le Page
    Centre de Recherche du Centre Hospitalier de l Université de Montréal Institut du cancer de Montréal, Montreal, Quebec, Canada
    Cancer Epidemiol Biomarkers Prev 17:913-20. 2008
    ..05, log-rank test) and Cox univariate as well as in multivariate analyses with a higher hazard ratio than clinical variables, such as residual disease, age, stage, and grade...
  83. ncbi Lactase persistence and ovarian carcinoma risk in Finland, Poland and Sweden
    Mikko Kuokkanen
    National Public Health Institute, Department of Molecular Medicine, Helsinki, Finland
    Int J Cancer 117:90-4. 2005
    ..65-4.08, p=0.29). Our results do not support the hypothesis that lactase persistence increases the ovarian carcinoma risk. On the contrary, lactase persistence may decrease the ovarian carcinoma risk at least in the Finnish population...
  84. ncbi Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy
    K Fujiwara
    Department of Obstetrics and Gynecology, Kawasaki Medical School, 577 Matsushima, Kurashiki City 701 0192, Japan
    Int J Gynecol Cancer 12:250-6. 2002
    ....
  85. ncbi Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer
    R Shimogai
    Department of Obstetrics and Gynecology, Tottori University, School of Medicine, Nishimachi, Yonago, Japan
    Int J Gynecol Cancer 18:499-505. 2008
    ..The present study suggested that the expression level of HIF-1alpha could be an independent prognostic factor in epithelial ovarian cancer...
  86. pmc A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer
    Edwin M Posadas
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Cancer 109:1323-30. 2007
    ..The secondary objectives included assessing clinical activity and toxicity and determining the association between biochemical and clinical outcomes...
  87. ncbi Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study
    Russell J Schilder
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3418-25. 2008
    ..The association between the expression of certain markers and clinical outcome was investigated...
  88. ncbi Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome
    Ritu Salani
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Cancer 109:685-91. 2007
    ....
  89. ncbi High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels
    J M Lancaster
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, 33612, USA
    Int J Gynecol Cancer 16:1529-35. 2006
    ..Further, IGFBP-2 may represent an additional serum biomarker with utility in detection and monitoring of epithelial ovarian cancer...
  90. ncbi Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors
    W Glenn McCluggage
    Department of Pathology, Royal Group of Hospitals Trust, Belfast, Northern Ireland
    Semin Diagn Pathol 22:3-32. 2005
    ....
  91. ncbi Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases
    Emanuela Veras
    Department of Pathology, The University of Texas Medical School at Houston, Houston, TX 77030, USA
    Am J Surg Pathol 31:774-82. 2007
    ....
  92. ncbi Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei
    Jesse K McKenney
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Am J Surg Pathol 32:645-55. 2008
    ..In contrast, teratomas with an invasive carcinomatous component and microscopic peritoneal carcinomatosis follow an aggressive clinical course...
  93. ncbi INI1 and GLUT-1 expression in epithelioid sarcoma and its cutaneous neoplastic and nonneoplastic mimics
    Jared M Orrock
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Dermatopathol 31:152-6. 2009
    ..In contrast, there does not seem to be a role for GLUT-1 immunohistochemistry in this differential diagnosis...
  94. ncbi The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis
    Charles M Quick
    Department of Pathology, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Hum Pathol 41:1145-9. 2010
    ..In addition, these data add further support to the proposed embryogenesis of the prostatic central zone, seminal vesicle, and ejaculatory ducts from the wolffian system...
  95. ncbi Paneth cell differentiation in colonic epithelial neoplasms: evidence for the role of the Apc/beta-catenin/Tcf pathway
    Mee Joo
    Department of Pathology, Inje University Ilsan Paik Hospital, Daehwa dong, Ilsanseo gu, Goyang si, Gyeonggi Do, Republic of Korea
    Hum Pathol 40:872-80. 2009
    ..Activation of Apc/beta-catenin/Tcf pathway may play a role in Paneth cell differentiation in human colonic neoplasms...
  96. pmc Middle ear glandular neoplasms: adenoma, carcinoma or adenoma with neuroendocrine differentiation: a case series
    Issam Saliba
    Department of Otorhinolaryngology, Head and Neck Surgery, Montreal University Hospital Center CHUM, Hotel Dieu Hospital, Montreal, Quebec, Canada
    Cases J 2:6508. 2009
    ....
  97. ncbi Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases
    Robert A Soslow
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 32:1013-21. 2008
    ..ER, PR, and CD10 expression was lost in MA-SOs relative to conventional low-grade stromal areas of mullerian/mesodermal adenosarcomas, reflecting the "dedifferentiation" of this component...
  98. ncbi Thyroid transcription factor-1 expression in normal gynecologic tissues and its potential significance
    Hui Lin Niu
    Department of Pathology, Guangzhou Children s Hospital, China
    Int J Gynecol Pathol 28:301-7. 2009
    ..The high TTF-1 expression in tubal epithelium but not in normal ovarian surface epithelium suggests that some TTF-1-positive ovarian tumors might be related to the tubal epithelium...
  99. ncbi Spontaneous skin neoplasms in aged Sprague-Dawley rats
    G M Zwicker
    Toxicology Department, Marion Merrell Dow, Inc, Indianapolis, Indiana 46268
    Toxicol Pathol 20:327-40. 1992
    ..Epithelial neoplasms of the skin were 6 times more common in males than in females. Males were more than twice as likely to have epithelial rather than mesenchymal skin neoplasms whereas the reverse was seen in females...
  100. ncbi Chronological trend of calorie intake and the incidence of epithelial neoplasms of the large intestine during the past 30 years in Japan
    Kyotaro Kanazawa
    Department of Gastroenterological and General Surgery, Jichi Medical School, Tochigi, Japan
    Oncology 69:46-9. 2005
    ..The authors tried to elucidate the effects of food intake on the incidences of colorectal cancer and adenoma...
  101. ncbi Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary
    Ghada E Esheba
    Department of Pathology, Stanford University, Stanford, CA 94305, USA
    Am J Surg Pathol 32:600-7. 2008
    ..0001). Because GPC3 may be associated with alpha-fetoprotein expression, further studies are required to determine the utility of GPC3 in differentiating YST from CCC with hepatoid differentiation...

Research Grants63

  1. Regulation of Inflammation-Associated Epithelial Cancer Development
    Lisa Marie Coussens; Fiscal Year: 2012
    ..abstract_text> ..
  2. Regulators of Epithelial Tumor Progression
    Paul A Khavari; Fiscal Year: 2013
    ..This proposal aims to characterize mediators of tumor-stroma interactions at the BM as a foundation for future strategies for cancer prevention and treatment. ..
  3. Nonlinear Optical Staging of Epithelial Neoplasms
    Gracie Vargas; Fiscal Year: 2012
    ..Despite occurring in a highly accessible tissue for inspection high mortality and morbidity rates, particularly following recurrence, indicate the need for improved detection and staging of oral neoplasia. ..
  4. Acoustic Imaging of Sentinel Node Matastasis using Plasmonic Nanosensors
    Konstantin V Sokolov; Fiscal Year: 2013
    ..Furthermore, we will design and construct a prototype of the clinical MS-USPAL imaging system capable of imaging 5 nm nanoparticles in-vivo. ..
  5. Influence of acid reflux on stromal epithelial interaction in Barrett?s esophagus
    GANAPATHY PRASAD; Fiscal Year: 2009
    ..Project Narrative The purpose of this study is to determine the association between acid reflux and cell changes in Barrett's esophagus. ..
  6. Pathology of Aging Flies
    Robert Salomon; Fiscal Year: 2005
    ..We anticipate that we will characterize new targets for the experimental modulation of the aging process in one of the world's best-studied and most tractable model organisms. ..
  7. CYLD Regulation of Epidermal Growth and Neoplasia
    YUNYAN JENNIFER ZHANG; Fiscal Year: 2009
    ....
  8. Novel Immunotherapy for the treatment of cervical cancer
    Vafa Shahabi; Fiscal Year: 2005
    ..In addition, this technology can be applied to other cancers and infectious diseases, projects that are in preclinical development. ..
  9. QB CYTOLOGY, METHOD FOR DETECT CIRCULATING CANCER CELLS
    David Rimm; Fiscal Year: 2000
    ..Given recent literature suggesting that tumor cells may circulate before metastasis, we also project future testing of this assay as screening test for early detection of solid tumors. ..
  10. Genetic Analysis of the Sonic Hedgehog Target Gene BEG4
    Christopher Callahan; Fiscal Year: 2005
    ..The proposed research fellowship will yield new insights into the pathogenesis of BCCs and other Shh pathway-related malignancies and may lead to the identification of new targets for prevention and therapy. ..
  11. MECH OF RAS MEDIATED APOPTOSIS BY INHIBITION OF NFKB
    Cun Yu Wang; Fiscal Year: 1999
    ....
  12. Id1 regulation of keratinocyte growth
    Rhoda Alani; Fiscal Year: 2003
    ....
  13. Endothelial Regulation of T Cell Homing in Ovarian Carcinoma
    George Coukos; Fiscal Year: 2007
    ..Results obtained from the proposed studies will generate novel ideas for the development of molecular tools to circumvent impediments to tumor immunotherapy. ..
  14. Use of Antidepressants and Risk of Breast Cancer
    MARY ROSSING; Fiscal Year: 2003
    ..g., SSRIs or tricyclics), and individual drugs such as fluoxetine and paroxetine. Use of the pharmacy database will provide unbiased and complete exposure data relative to previous studies based on self-reported drug use. ..
  15. Vascular Leukocytes Induce regulatory T cells (Treg) in Tumors
    George Coukos; Fiscal Year: 2010
    ....
  16. EPIDEMIOLOGY OF SMOKING CESSATION--GENETIC INFLUENCES
    MARY ROSSING; Fiscal Year: 2002
    ..In the future, such knowledge may allow the identification of subgroups of individuals who are most likely to benefit from particular pharmacologic interventions. ..
  17. Epidemiology of Ovarian Cancer:New Hypotheses
    MARY ROSSING; Fiscal Year: 2006
    ..abstract_text> ..
  18. Steroid Hormone Genes and Ovarian Cancer Risk
    Mary Anne Rossing; Fiscal Year: 2010
    ..The proposed study, by expanding our knowledge of the role of progestogens, estrogens, and androgens in the development of ovarian cancer, will inform efforts to develop effective strategies to prevent this disease. ..
  19. Regulation of CSF-1 in Ovarian Cancer
    SETSUKO CHAMBERS; Fiscal Year: 2006
    ..Moreover, the results of these studies will provide the scientific basis for a future trial of anti-androgen therapy as a chemopreventative agent in patients at high risk for the development of ovarian cancer. ..
  20. Molecular Targeting of 15-Lipoxygenase-1 in Colon Cancer
    Imad Shureiqi; Fiscal Year: 2007
    ..the feasibility of tumor selective targeting of 15-LOX-1 to inhibit tumorigenesis will pave the way for future preclinical and clinical development of therapeutic strategies based on molecularly targeting 15-LOX-1 ..
  21. Development and testing of a silibin-containing sunscreen
    L Glode; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  22. Postmarketing Surveillance of Toxicities Associated with Cancer Chemotherapy
    Xianglin Du; Fiscal Year: 2010
    ..This database is especially unique for studying cancer chemotherapy and its toxicity because chemotherapy is among the few drugs that are covered by Medicare for past several decades. ..
  23. HOX genes in ovarian neoplasia
    Honami Naora; Fiscal Year: 2008
    ..abstract_text> ..
  24. 5-LOX-1 and Clinical Chemoprevention of Colon Tumors
    Imad Shureiqi; Fiscal Year: 2008
    ..If our hypothesis is confirmed, efforts can be directed to develop chemopreventive interventions that specifically target the GATA-6 and 15-LOX-1 signaling pathway. ..
  25. Dendritics Cell Immunotherapy for Colorectal Cancer
    Lawrence Fong; Fiscal Year: 2008
    ..The proposed studies will provide the foundation for a more potent DC targeted cancer immunotherapy for the future. [unreadable] [unreadable] [unreadable]..
  26. High Throughput Screen for JAK2V617F Mutant Selective Inhibitors
    Ross Levine; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  27. Coherence Imaging for Assessing Colorectal Neoplasia
    Adam Wax; Fiscal Year: 2010
    ..abstract_text> ..
  28. Tumor metastasis: Biobehavioral mechanisms
    Anil K Sood; Fiscal Year: 2009
    ....
  29. Skin Manifestations of Tuberous Sclerosis
    Jack Arbiser; Fiscal Year: 2009
    ..Specific Aim 3. To determine whether dysregulation of p16ink4a and PTCH (patched) acts as a modifier of theTS phenotype in transgenic mice expressing dominant negative tuberin. ..
  30. Adolescent Gastric By-Pass and Diabetic Precursors
    Thomas Inge; Fiscal Year: 2006
    ....
  31. CASE CONTROL STUDY OF OVARIAN CANCER HORMONAL ETIOLOGY
    Harvey Risch; Fiscal Year: 2002
    ....
  32. Ovarian Cancer Detection Using H-NMR_Based Metabonomics
    Kunle Odunsi; Fiscal Year: 2006
    ..The proposed studies may lead to the identification of novel biomarkers for early detection of EOC, that will be evaluated further in prospective studies for early detection of EOC in general and high-risk populations. ..
  33. Roles of polycystin and calcium in B-Raf signaling
    DARREN WALLACE; Fiscal Year: 2004
    ..2) Determine the mechanism by which the overexpression of the C-terminal fragment of PC1 in M1 cells, a condition thought to disrupt PC1/PC2 function, alters cAMP-dependent B-Raf signaling. ..
  34. ATR in Human Cancer and Anticancer Therapy
    William Cliby; Fiscal Year: 2004
    ..Using xenograft models we will develop a gene therapy model of ATR disruption to test the safety and efficacy of targeting ATR for anticancer therapy. ..
  35. Colorectal Screening Capacity Building Conference
    David Alberts; Fiscal Year: 2003
    ..Continued capacity building and future collaboration will also be woven into this conference to serve as a stone to build upon in the future. ..
  36. Meeting of American Society for Reproductive Immunology:
    Gil Mor; Fiscal Year: 2003
    ..abstract_text> ..
  37. Imprinted PEG3 domain at 19q13.4 and carcinogenesis
    Susan Murphy; Fiscal Year: 2002
    ..These studies will help clarify the role of the human PEG3 isoforms in the control of cellular growth, and may further contribute potential diagnostic and therapeutic targets for ovarian cancer. ..
  38. IMMUNE ACCEPTANCE OF PREGNANCY
    Gil Mor; Fiscal Year: 2002
    ..The significance of this proposal is not limited to reproductive problems. It is anticipated that these studies will lead to a better understanding of tumor behavior, actions of chemotherapeutic agents and transplant physiology. ..
  39. TCR DNA IMMUNIZATION FOR 2B411 T CELL LYMPHOMA
    Michael Girardi; Fiscal Year: 2002
    ....
  40. DNA POLYMORPHISMS IN OVARIAN CANCER--CASE CONTROL STUDY
    Harvey Risch; Fiscal Year: 2002
    ..abstract_text> ..
  41. LINOLEIC ACID METABOLISM AND COLON CARCINOGENESIS
    Imad Shureiqi; Fiscal Year: 2005
    ..This work will set the stage for future animals and clinical studies of LA alternative pathway modulation as means of colon cancer chemoprevention. ..
  42. Angiogenesis Targeted Therapeutics of Ovarian Cancer
    Robert Burger; Fiscal Year: 2006
    ..Finally, Dr. Burger will generate a logical sequence of original publications and extramural funding specific to the proposed work. ..
  43. Proteomic analysis of head & neck squamous cell cancer
    Michael Prystowsky; Fiscal Year: 2005
    ....
  44. Evaluation of Chemotherapy Claims for Breast Cancer
    Xianglin Du; Fiscal Year: 2003
    ....
  45. MOLECULAR DISSECTION OF TUMOR INVASION
    SCOTT A GOODE; Fiscal Year: 2010
    ..These aims will delineate the first pathway by which basolateral junctions control epithelial invasiveness, which may provide important tools for diagnosis and treatment of invasive cancers. ..
  46. Phase II trial of HSPE7 for treatment of CIN II/III
    ELLEN SHEETS; Fiscal Year: 2002
    ..Spectroscopic changes in the epithelium, development of HPV specific mucosal and systemic T cell responses and levels of HPV16 E2 specific antibody in cervical secretions will be evaluated as potential correlates of response. ..
  47. Phase ii intraperitoneal rhIL 12
    Ralph Freedman; Fiscal Year: 2002
    ..4) Determine whether expression of proangiogenic factors VEGF, FGF2 and IL-8 are decreased following IF rhIL- 12. ..
  48. Urine Protein Biomarker Exploration in Ovarian Cancer
    Bin Ye; Fiscal Year: 2006
    ..This project, if successful, could fundamentally shift the approach to the early detection of ovarian cancer and significantly improve the survival rate of cases detected. [unreadable] [unreadable]..
  49. Elucidating modulators of hepatic metabolism by quantitative flux analysis
    Gregory Stephanopoulos; Fiscal Year: 2010
    ..Ultimately, we aspire to establish flux quantification as an indispenable tool in biomedical research. ..
  50. Ovarian Cancer: Strategies for consolidation
    Paul Sabbatini; Fiscal Year: 2006
    ..Promising strategies will be moved to patients in primary remission (Specific Aim 1) with a current median time to treatment failure of 18-21 months...
  51. A1 REGULATED LEUKOCYTE APOPTOSIS DURING INFLAMMATION
    Michael Prystowsky; Fiscal Year: 2001
    ..3) Protection of macrophages during inflammation is mediated by A1 and is vital for host defense. ..
  52. Strategies Against HPV Related Genital Diseases in Women
    Bradley Monk; Fiscal Year: 2006
    ..It is expected that Dr. Monk will have obtained extramural funding for both his laboratory and clinical studies by the end of the period of support requested. ..
  53. Assessing nuclear morphology in thick tissues using fLCI
    Adam Wax; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  54. Microvascular Perfusion Sonographic Imaging to Detect Early Stage Ovarian Cancer
    David Fishman; Fiscal Year: 2008
    ..These studies to accurately detect early stage EOC, if successful will have a significant impact on the morbidity and mortality associated with EOC. ..
  55. In vivo detection of pre-cancerous lesions using a/LCL
    Adam Wax; Fiscal Year: 2008
    ..abstract_text> ..
  56. Assessing Deployment of Microbicidal Gels With Label-Free Optical Measurement
    Adam Wax; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  57. Biobehavioral-Cytokine Interactions in Ovarian Cancer
    Susan Lutgendorf; Fiscal Year: 2007
    ..Findings will have implications for innovative behavioral and pharmacological intervention strategies for ovarian cancer patients. ..
  58. Cytotoxic Gonadotropin Releasing Hormone Derivatives
    L Glode; Fiscal Year: 2003
    ..This would result in a superior, non-surgical and cost-effective means of treating these cancers. ..
  59. DIET AND DURATION OF CERVICAL HPV INFECTION
    MARC GOODMAN; Fiscal Year: 2009
    ....
  60. Healing Touch and Immunity in Advanced Cervical Cancer
    Susan Lutgendorf; Fiscal Year: 2002
    ....